ACTR-21. UPDATED RESULTS OF A PHASE I DOSE-ESCALATION, DOSE-EXPANSION STUDY OF DISULFIRAM AND ADJUVANT TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA

Lignende værker

• ATNT-11 A PHASE I PHARMACODYNAMIC STUDY OF DISULFIRAM AND TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA AFTER RADIATION THERAPY AND CONCURRENT TEMOZOLOMIDE
  af: Huang, Jiayi, et al.
  Udgivet: (2015)
• Concurrent Temozolomide and Dose-Escalated Intensity Modulated Radiation Therapy in Newly Diagnosed Glioblastoma
  af: Tsien, Christina I., et al.
  Udgivet: (2011)
• ACTR-07. LIMITED IMPACT OF EXTENDED ADJUVANT TEMOZOLOMIDE BEYOND 12 CYCLES IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMAS
  af: Ohno, Makoto, et al.
  Udgivet: (2017)
• ACTR-48. FEASIBILITY OF DISCONTINUATION OF ADJUVANT TEMOZOLOMIDE AFTER 12 CYCLES REMAINING WITHOUT PROGRESSION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
  af: Nagane, Motoo, et al.
  Udgivet: (2018)
• ACTR-19. A MULTICENTER PILOT PHASE II STUDY OF CONTINUING TMZ WITH THE ADDITION OF DISULFIRAM AND COPPER FOR REFRACTORY GLIOBLASTOMA
  af: Huang, Jiayi, et al.
  Udgivet: (2018)